Comparative Acute Effects of R-MDMA and S-MDMA in Healthy Participants

Status: Recruiting
Location: See location...
Intervention Type: Drug, Other
Study Type: Interventional
Study Phase: Phase 1
SUMMARY

Racemic ±3,4-methylenedioxymethamphetamine (MDMA) is a psychoactive substance and prototypical empathogen acutely inducing feelings of heightened mood, empathy, trust and closeness to others. These acute subjective effects of MDMA may be helpful to assist psychotherapy and MDMA has been investigated in phase 3 trials as a possible treatment in post-traumatic stress disorder.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 65
Healthy Volunteers: t
View:

• Age between 18 and 65 years

• Good understanding of the German language

• Understanding of procedures and risks associated with the study

• Willing to adhere to the protocol and signing of the consent form

• Willing to refrain from the consumption of illicit psychoactive substances during the study

• Willing not to operate heavy machinery within 48 h after administration of a study substance (including driving a car)

• Willing to use effective birth-control throughout study participation.

• Body mass index 18 - 34.9 kg/m2

Locations
Other Locations
Switzerland
University Hospital Basel
RECRUITING
Basel
Contact Information
Primary
Matthias E Liechti, Prof. Dr. MD
matthias.liechti@usb.ch
61 328 68 68
Backup
Carolin R Mayer
carolinrenate.mayer@usb.ch
61 328 68 65
Time Frame
Start Date: 2025-07-29
Estimated Completion Date: 2026-11
Participants
Target number of participants: 24
Treatments
Experimental: 300mg R-MDMA
R-MDMA (300mg)
Experimental: 100mg S-MDMA
S-MDMA (100mg)
Placebo_comparator: Placebo
Placebo
Related Therapeutic Areas
Sponsors
Leads: University Hospital, Basel, Switzerland

This content was sourced from clinicaltrials.gov

Similar Clinical Trials